- Home
- NERV vs HCWB Comparison
NERV vs HCWB Comparison
Compare NERV & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- HCWB
- Stock Information
- Founded
- NERV 2007
- HCWB 2018
- Country
- NERV United States
- HCWB United States
- Employees
- NERV N/A
- HCWB N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- HCWB Health Care
- Exchange
- NERV Nasdaq
- HCWB Nasdaq
- Market Cap
- NERV 12.0M
- HCWB 10.8M
- IPO Year
- NERV 2014
- HCWB 2021
- Fundamental
- Price
- NERV $2.35
- HCWB $4.24
- Analyst Decision
- NERV Hold
- HCWB Strong Buy
- Analyst Count
- NERV 1
- HCWB 1
- Target Price
- NERV $5.00
- HCWB $35.00
- AVG Volume (30 Days)
- NERV 41.4K
- HCWB 4.5M
- Earning Date
- NERV 11-04-2025
- HCWB 08-18-2025
- Dividend Yield
- NERV N/A
- HCWB N/A
- EPS Growth
- NERV N/A
- HCWB N/A
- EPS
- NERV 1.48
- HCWB N/A
- Revenue
- NERV N/A
- HCWB $832,841.00
- Revenue This Year
- NERV N/A
- HCWB $178.36
- Revenue Next Year
- NERV N/A
- HCWB N/A
- P/E Ratio
- NERV $1.58
- HCWB N/A
- Revenue Growth
- NERV N/A
- HCWB N/A
- 52 Week Low
- NERV $1.15
- HCWB $2.77
- 52 Week High
- NERV $3.00
- HCWB $100.80
- Technical
- Relative Strength Index (RSI)
- NERV 59.22
- HCWB 44.06
- Support Level
- NERV $2.26
- HCWB $5.47
- Resistance Level
- NERV $2.47
- HCWB $6.66
- Average True Range (ATR)
- NERV 0.15
- HCWB 0.73
- MACD
- NERV -0.01
- HCWB -0.00
- Stochastic Oscillator
- NERV 36.71
- HCWB 32.10
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.